Characterization and Functional Analysis of Extracellular Vesicles and Muscle-Abundant miRNAs (miR-1, miR-133a, and miR-206) in C2C12 Myocytes and mdx Mice

Yasunari Matsuzaka1, Jun Tanihata2, Hirofumi Komaki3, Akihiko Ishiyama3, Yasushi Oya4, Urs Rüegg5, Shin-ichi Takeda2, Kazuo Hashido1*

1 Administrative Section of Radiation Protection, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan, 2 Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan, 3 Department of Child Neurology, Hospital, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan, 4 Department of Neurology, Hospital, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan, 5 Department of Pharmacology, Geneva-Lausanne School of Pharmaceutical Sciences, University of Geneva and University of Lausanne, Geneva, Switzerland

* hashido@ncnp.go.jp

Abstract

Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disorder. Here, we show that the CD63 antigen, which is located on the surface of extracellular vesicles (EVs), is associated with increased levels of muscle-abundant miRNAs, namely myomiRs miR-1, miR-133a, and miR-206, in the sera of DMD patients and mdx mice. Furthermore, the release of EVs from the murine myoblast C2C12 cell line was found to be modulated by intra-cellular ceramide levels in a Ca2+-dependent manner. Next, to investigate the effects of EVs on cell survival, C2C12 myoblasts and myotubes were cultured with EVs from the sera of mdx mice or C2C12 cells overexpressing myomiRs in presence of cellular stresses. Both the exposure of C2C12 myoblasts and myotubes to EVs from the serum of mdx mice, and the overexpression of miR-133a in C2C12 cells in presence of cellular stress resulted in a significant decrease in cell death. Finally, to assess whether miRNAs regulate skeletal muscle regeneration in vivo, we intraperitoneally injected GW4869 (an inhibitor of exosome secretion) into mdx mice for 5 and 10 days. Levels of miRNAs and creatine kinase in the serum of GW4869-treated mdx mice were significantly downregulated compared with those of controls. The tibialis anterior muscles of the GW4869-treated mdx mice showed a robust decrease in Evans blue dye uptake. Collectively, these results indicate that EVs and myomiRs might protect the skeletal muscle of mdx mice from degeneration.

Introduction

Duchenne muscular dystrophy (DMD; OMIM #310200) is an X-linked recessive, severe and progressive muscle disease with a prevalence of 1 in 3,500 live male births, and is caused by
mutations in the dystrophin gene [1,2]. This disorder is usually first recognized by muscular weakness from two to five years of age. Subsequently, patients lose their ability to ambulate before 12 years of age, and eventually experience failure of respiratory and cardiac functions owing to degeneration of the diaphragm and cardiac muscles [3]. Serum creatine kinase (CK), which reflects the level of muscle damage, is commonly used as a diagnostic marker for DMD. However, false-positive or false-negative results are commonly observed, because CK release is increased by various factors, such as vigorous exercise [4], and is decreased by disease progression with age following the loss of muscle tissue [5], rendering quantitative diagnosis and prognostic applications of CK difficult. Thus, reliable biomarkers of DMD have been anticipated.

miRNAs are non-coding single stranded RNAs containing approximately 21 to 24 nucleotides, which regulate gene expression by base-pairing of their nucleotides 2 to 8 with the 5' or 3'-untranslated regions of target mRNAs, primarily in the cytoplasm [6–8]. As the activities of approximately 50% of all coding genes in mammals are predicted to be regulated by miRNAs, the dysregulation of their expressions is associated with the pathophysiological conditions of many disorders. Some miRNAs are encapsulated into microvesicles, exosomes, or apoptotic bodies, whereas other miRNAs form complexes with RNA-binding proteins [9–16]. They can be internalized by recipient cells via extracellular vesicles (EVs), leading to the intercellular communication [13–18]. Despite the high levels of RNase activity within the circulating blood, because miRNAs are protected from RNase by their association with RNA-binding protein(s) or their inclusion within EVs, remarkably stable miRNAs were shown to be secreted into the extracellular space in non-vesicular or vesicular-encapsulated forms [19–21]. Several groups, including our own, previously reported that three myomiRs, namely, miR-1, miR-133a, and miR-206, were increased in the sera of animal models of muscular dystrophy as well as in patients [22–24]. This upregulation in myomiR levels is not limited to DMD patients, as increased levels of miR-1 were found in the sera of Becker muscular dystrophy (BMD), facioscapulohumeral muscular dystrophy, and limb-girdle muscular dystrophy patients, and increased levels of miR-133a and miR-206 were found in BMD patients [25]. In addition, myomiR levels were shown to be inversely correlated with disease severity in DMD patients aged three to six years [22].

The increased levels of myomiRs in the sera of mdx mice have been demonstrated to be increased to near wild-type levels by restoration of the dystrophin protein using exon-skipping therapies [26]. On the other hand, in the muscle of mdx mice, miR-1 and miR-133a levels have been shown to be downregulated, whereas miR-206 levels are upregulated [26, 27]. The expression of miR-1 and miR-133a in skeletal muscle can be restored by rescue of the dystrophin protein using exon-skipping techniques [27, 28]. These myomiRs have multiple roles in muscle development and regeneration, such as the regulation of genes involved in myogenesis, proliferation, and muscle fiber-type conversion [29, 30]. Thus, miRNAs have been acknowledged not only as noninvasive biomarkers of DMD, but also as therapeutic targets for many disorders. However, the potential involvement of these muscle-abundant miRNAs in the pathogenesis of DMD remains unclear. Elucidating the pathways regulating the release of myomiRs will be valuable towards gaining a better understanding of DMD pathogenesis and new targets for therapies. In fact, the release of miRNAs into intracellular and extracellular spaces was shown to be controlled by the neutral sphingomyelinase 2/sphingomyelin phosphodiesterase 3 (nSMase2/SMPD3)-regulated secretory machinery of exosomes, which are membrane microvesicles about 30–100 nm in size generated from multivesicular bodies (MVBs) of the terminal endosomal pathway via the biogenesis of ceramide from sphingomyelin [31–35]. However, the mechanisms regulating the functions of myomiRs transported via EVs, including exosomes or larger vesicles, in the pathogenesis of mdx mice remain largely unknown. In the present study, we show that the release of EVs from C2C12 cells is regulated by ceramide
metabolism in an intracellular Ca\(^{2+}\) concentration-dependent manner. The transport of miR-133a via EVs regulates the viability of C\(_{2}\)C\(_{12}\) cells under conditions of cellular stress. In addition, the inhibition of ceramide synthesis by GW4869 (an inhibitor of exosome secretion), leading to the suppression of EV secretion, reduces muscle degeneration in mdx mice. Our findings demonstrate the potential of myomiRs as a novel noninvasive biomarker and the regulation of myomiR levels as a new therapeutic strategy for DMD.

Materials and Methods

Antibodies and reagents

Primary antibodies against mouse CD63 (3H1626), rabbit apolipoprotein A-I (apoA-I) (FL-267), and rabbit CD81 (H-121), and the anti-rat IgG- Horseradish peroxidase (HRP) secondary antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse primary antibody against MHC class II (M5/114.15.2) was purchased from Novus Biologicals (Littleton, CO). Rabbit primary antibody against caveolin-3 was synthesized by Eurofins Genomics K.K. (Tokyo, Japan). Rabbit primary antibody against flotillin-1 was purchased from Bioss USA (Woburn, MA), and the anti-mouse IgG (H+L) HRP secondary antibody was purchased from Bio-Rad Laboratories, Inc. (Berkeley, CA). Anti-rabbit IgG HRP-linked secondary antibody was purchased from Cell Signaling Technology, Inc. (Beverly, MA). Anti-LAMP2 (M3/84) and anti-GAPDH (EPR6256) antibodies were purchased from Abcam (Cambridge, UK). Mouse monoclonal antibody against CD9 (IVA50) was purchased from Abnova (Taipei City, Taiwan). Mouse monoclonal antibody against calnexin (4F10) was purchased from MBL Laboratories CO., LTD (Nagoya, Japan). Mouse monoclonal antibody against HSP90 (H9010) was purchased from StressMarq Biosciences Inc. (Victoria, Canada). Actinomycin D was purchased from Focus Biomolecules (Plymouth Meeting, PA). Methyl-ß-cyclo-dextrin, 2-aminoethyl diphenylborinate (2-APB), A23187, C6-ceramide, and monensin sodium salt were purchased from Sigma-Aldrich (St. Louis, MO). BAPTA-acetoxymethyl ester and EGTA-acetoxymethyl ester were purchased from DOJINDO Laboratories (Kumamoto, Japan). C2-ceramide and simvastatin were purchased from Focus Biomolecules. Anhydrous caffeine was purchased from Nacalai Tesque (Kyoto, Japan). Cyclopiazonic acid, D-erythro-MAPP, ebseln, nocardazole, and U-0126 were purchased from Cayman Chemical Company (Ann Arbor, MI). GW4869 was purchased from Calbiochem (San Diego, California). Sphingosine-1-phosphate (S1P) was purchased from LKT Laboratories, Inc. (St Paul, MN).

Patients

Five unrelated Japanese patients with DMD and four healthy controls were enrolled in this study with the approval of the Ethics Committee of the National Center of Neurology and Psychiatry (approval ID: A2011-113), which followed regulation of Helsinki Declaration. All results are treated with standard medical confidentiality and confidential to the extent allowed by law. Written informed consent was obtained from all participants after explaining the details of the study, prior to the collection of peripheral blood.

Animals

All animals used in this study were housed in a specific pathogen free facility of the National Center of Neurology and Psychiatry and treated in accordance with the guidelines provided by the Ethics Committee for the Treatment of Laboratory Animals of the National Center of Neurology and Psychiatry (approval ID: 2013007), which has adopted the three fundamental principles of replacement, reduction, and refinement. Consistent with the approvals stipulated by
the protocol, all efforts were made to minimize suffering or discomfort to the animals. mdx mice with C57BL/6 background, transgenic mdx mice overexpressed dystrophin gene which lack coding region from exon 45 to exon 55 by CAG promoter with C57BL/6 background (Tanihata J. et al. in preparation of manuscript), and age-matched wild-type C57BL/6 male control mice were used in this study.

**Immunoprecipitation**

Two μg of antibodies were mixed with 0.1 mL of sera, and incubated at 4˚C overnight. Protein G Sepharose (100 μL; Sigma-Aldrich) was added to the sera, mixed well, and then incubated at 4˚C for 60 min. The immunoprecipitated complexes were collected by centrifugation at 3,000 × g for 2 min at 4˚C, and the supernatant was discarded. The pellet was then resuspended in 100 μL of 5% sodium dodecyl sulphate (SDS) solution, heated at 95˚C for 5 min, and centrifuged for 1 min at 12,000 × g at room temperature, and then the supernatant was collected as the immunoprecipitated samples.

**Extraction and quantification of miRNA**

Total RNA was extracted from 0.1 μL of serum using the mirVana miRNA isolation kit (Ambion, Austin, TX, USA) as 25 μL of RNA eluate according to the manufacturer’s protocol. RNA eluate (4.5 μL) was reverse transcribed using the TaqMan miRNA Reverse Transcription kit (ABI, Foster City, CA) and miRNA-specific stem-loop primers (part of the TaqMan miRNA assay kit, ABI) as previously described (21). The expression levels of miRNA were quantified by real-time PCR using individual miRNA-specific primers (part of TaqMan miRNA assay kit, ABI) with StepOne™ Real-Time PCR System (ABI) according to the manufacturer’s protocol. Samples were subjected to real-time PCR in triplicate. The expression of each miRNA was represented as relative values normalized by the expression of miR-16 and cel-miR-39 used as an internal control and spike-in miRNA, respectively. Data analysis was performed by SDS 2.1 real-time PCR data analysis software (ABI). Expression data are shown as median values obtained from three samples together with the standard deviation.

**Purification and quantitation of EVs**

Serum was harvested from the peripheral blood of DMD patients in tubes by centrifugation at 3,000 × g for 15 min. Isolation of exosomes from serum was performed by Total Exosome Isolation reagent (Invitrogen) or ExoQuick-LP™ (System Bioscience, Palo Alto, CA), according to the manufacturer’s protocol. Briefly, 50 μL of Total Exosome Isolation solution or 63 μL of ExoQuick solution were added to 250 μL of serum. The mixture was vortexed for 15 seconds and then incubated at 4˚C for 30 min. After centrifugation at 10,000 × g for 10 min at room temperature, the supernatant was discarded. The centrifugation and aspiration steps were repeated. The pellet containing the EVs was resuspended in 1× PBS. EVs were also isolated from C2C12 cells, which were conditioned in serum-free media for 24 hr at 90% confluence. Media were harvested, and then centrifuged at 2000 × g for 30 min to remove cells and debris. EVs were then isolated using Total Exosome Isolation reagent (Invitrogen). Briefly, the Total Exosome Isolation reagent (1/5 voulume) was added to cell-free culture media. The solution was vortexed for 15 seconds, and then incubated at 4˚C overnight. After centrifugation at 10,000 × g for 1 hour at 4˚C, the supernatant was discarded. Again, the centrifugation and aspiration steps were repeated. The pellet containing the EVs was resuspended in 1 × PBS and then filtered through a 0.22 μm filter, Millex-GV (Millipore Corporation, Billerica, MA). The EVs were confirmed using antibodies against exosomal marker proteins as well as flow cytometry.
Briefly, recovered exosomes were incubated with 4-μm diameter aldehyde/sulfate latex beads, 4% w/v, (Thermo Fisher Scientific, Waltham, MA) for 15 min at room temperature. The mixture was then mixed in a final volume of 200 μL of PBS at room temperature under gentle agitation. Two hours later, the reaction was terminated by the addition of 100mM glycine for 30 min at room temperature. After centrifugation, the pellet was washed in PBS containing 0.5% of bovine serum albumin and then incubated with specific antibodies. Beads were analyzed by flow cytometry using a BD Biosciences FACSCalibur using FACSDiva version 6.0 software. Concentrations of the EVs were then determined indirectly by quantifying protein concentrations. The amount of released EVs was quantified by measuring the activity of acetylcholinesterase (AChE) (Sigma-Aldrich), as previously described [36]. The total amount of EVs isolated from the culture media was suspended in 800 μL of PBS, and 100 μL of 12.5 mM acetylthiocholine and 100 μL of 1 mM 5,5'-dithio-bis (2-nitrobenzonic acid) (Sigma-Aldrich) was added in a final volume of 1 mL, and then the mixture was incubated at 37˚C for 30 min. The EV solution (300 μL each) was divided into 96-well plates in triplicate and then absorbance at 415 nm was measured on a 680 microplate reader (Bio-Rad Laboratories, Inc.).

**Dot blot analysis**

Ten μg/μL of EVs extracted from mouse serum was serially diluted in PBS. One μL of the EV solution was dotted onto an Immobilon-P transfer membrane, which is a microporous polyvinylidene fluoride membrane (Millipore Corporation, Billerica, MA). The membrane was dried at 60˚C for 10 minutes, and then incubated with primary antibodies (2 ug) at 4˚C overnight, and then with HRP-conjugated secondary antibodies at room temperature for 1 hr. Chemiluminescence was detected using ECL Prime Detection Reagent (GE Healthcare, Buckinghamshire, UK) and analyzed using LAS-3000 (Fujifilm Corporation, Tokyo, Japan).

**Western blotting analysis**

For Western blotting analysis, 50 μL of sera from mdx and wild-type (wt) mice were resolved by 12% SDS PAGE, and then transferred onto a Polyvinylidene Difluoride (PVDF) membrane (Merck Millipore, Billerica, MA). An anti-LAMP2 antibody (1:1,000 in a mixture of tris-buffered saline (TBS) and Polysorbate 20 (TBST)) and an anti-rat IgG-HRP antibody (1:1,000 in TBST) were used as first and secondary antibodies, respectively. Signal detection was performed using antibodies coupled to HRP and ECL Prime Detection Reagent (GE Healthcare, Buckinghamshire, UK), together with analysis by LAS-3000 (Fujifilm Corporation).

**Creatine kinase activity**

Serum CK levels were measured using the Fuji Dri-Chem system (Fujifilm Medical Co. Ltd., Tokyo, Japan) according to the manufacturer’s protocol. Serum (10 μL) was deposited on a Fuji Dri-Chem slide and incubated at 37˚C. The increase in absorbance by the generated dye was measured spectrophotometrically for 5 min at 540 nm and the activity was calculated according to the installed formula. Data were expressed as units per liter (U/L).

**Cell viability analysis**

C2C12 murine myoblast cells were cultured in Dulbecco’s Modified Eagle’s medium (DMEM; Sigma-Aldrich) with 10% (v/v) fetal bovine serum (Cell Culture Technologies, Lugano, Switzerland) and 1% (v/v) penicillin/streptomycin (Wako Pure Chemical Industries Ltd., Osaka, Japan) as the growth medium. The cells were grown at 37˚C in controlled humidified air with 5% CO₂. For myogenic differentiation of myoblasts into myotubes, the growth medium was...
changed to differentiation medium, namely, DMEM containing 2% heat-inactivated horse serum and 1% penicillin/streptomycin. Briefly, C2C12 cells were grown in 96-well plates (BM Equipment Co. Ltd., Tokyo, Japan) in growth medium until confluent and then changed to serum-free medium (DMEM containing 1% penicillin/streptomycin) and incubated with or without inducers or suppressors of EV secretion for the indicated times. The number of cells was determined by measuring the absorbance at 450 nm of the formazan product in the culture medium using a 680 microplate reader after incubation with 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt (WST-8) from Cell Counting Kit-8 (CCK-8) (DOJINDO Laboratories).

Transfection assay

Three DNA fragments, namely, precursors of miR-1a, miR-133a, and miR-206 (pre-miR-1a, pre-miR-133a, and pre-miR-206) were synthesized (Bioneer, Alameda, CA), and inserted into the intron site of the pEM-157 vector, which contains the cytomegalovirus promoter driving transcription of the dsRed-fluorescent protein-coding sequence interrupted by an intron. The sequences of the three fragments were as follows: pre-miR-1a: 5′-GTTTAACAGGCACTATAGATACCTGAGATGGGATGACGCACTAGT-3′, pre-miR-133a: 5′-GTTTAACAGGCACTATAGATACCTGAGATGGGATGACGCACTAGT-3′, pre-miR-206: 5′-GTTTAACAGGCACTATAGATACCTGAGATGGGATGACGCACTAGT-3′. C2C12 cells cultured in 24-well dishes were transfected with these plasmids using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. Briefly, 0.2 μg of each plasmid was diluted in 25 μL of Opti-MEM® I Reduced Serum Medium (Invitrogen). The plasmid solutions were mixed with 4 μL of PLUS™ Reagent (Invitrogen), and then incubated at room temperature for 15 min. After incubation, the plasmid solutions were mixed with 25 μL of Lipofectamine 2000, diluted 25 times by Opti-MEM® I Reduced Serum Medium, and then incubated at room temperature for 15 min. The plasmid solutions were added to C2C12 cells in serum-free medium. After incubation at 37°C for 3 hrs, the medium was changed to growth medium, and then incubated at 37°C for the indicated times.

Caspase-3 assay

C2C12 myoblast cells were cultured to confluence in growth medium in 6-well plates, and then the growth medium was changed to serum-free medium (DMEM containing 1% penicillin/streptomycin with 0.5 mM of H2O2). The cells were incubated with or without EVs (4 μg) for 24 hours. Then, caspase-3 activity was quantified using the Caspase-3/CPP32 Colorimetric Assay Kit (BioVision Inc., Milpitas, CA). Briefly, cells were harvested, and the supernatant was removed by centrifugation. Pellets were suspended in 50 μL of chilled cell lysis buffer, and then incubated on ice for 10 min, and centrifuged for 1 min at 10,000 × g. Supernatants were transferred to fresh tubes, and protein concentrations were measured. Protein solutions were adjusted to a concentration of 100 μg/μL by dilution with PBS. Fifty μL of 2 × Reaction Buffer and 5 μL of 4 mM DEVD-pNA substrate were added to 50 μL of the protein solutions and then incubated at 37°C for 2 hrs. Caspase-3 activity was determined by measuring the absorbance at 405 nm using a 680 microplate reader.

Analysis of skeletal muscle regeneration of mdx mice

GW4869 was dissolved in dimethyl sulfoxide (DMSO) at a concentration of 1.5 mM, and then 2.5 μL of 5% methane sulfonic acid solution was added to 50 μL of the GW4869 solution,
resulting in a final concentration of 1.43 mM of GW4869. The solution was then incubated at 37°C until the color of the solution became clear, and the GW4869 solution was further diluted to 100 μM in PBS. One-hundred μL of this final GW4869 solution was intraperitoneally injected into mdx mice. After 5 or 10 days, whole body blood was collected from the abdominal aorta. Twenty-four hours before sacrifice, mice were injected intraperitoneally with 1% Evans blue dye (EBD; Nacalai Tesque) in PBS as described previously [37]. Muscles were harvested, frozen in melting isopentane, and sectioned. The muscle sections were incubated in ice-cold acetone for 10 min, washed three times for 10 min with PBS, and mounted with Vectorshied mounting medium. The presence of EBD in myofibers was analyzed by fluorescence microscopy.

Secondary structure of myomiRs
GC contents and ΔG were estimated using by a web tool, which is available free of charge at https://sg.idtdna.com/calc/analyzer.

Statistical analyses
Statistical analysis was performed by the Fisher’s exact probability test (P-value test) followed by Bonferroni correction (Pc). A Pc-value or P-value of less than 0.05 were considered to indicate a statistically significant difference between two groups.

Results
Expression levels of myomiRs and EV contents in sera of mdx mice and DMD patients
We previously showed that myomiRs in the serum of mice were upregulated by cardiotoxin-induced muscle injury [25]. It has also been reported that miR-1 and miR-133a levels are downregulated in dystrophic muscle and recover to normal levels by the rescue of dystrophin expression [26, 27]. To elucidate whether myomiR levels in the serum are positively associated with muscle degeneration, the levels of three myomiRs, namely, miR-1, miR-133a, and miR-206, in the sera of transgenic (tg) mdx mice, overexpressing a truncated dystrophin transcript with a deletion from exon 45 to 55, mdx mice, and wild-type (wt) mice were quantified by qRT-PCR. Consistent with a previous report [26], the levels of myomiRs in the serum of mdx mice were upregulated compared with those of wt mice, but the tg mice showed a decreased level compared with that of mdx mice (S1A Fig). Ubiquitously expressed miR-21, mir-29, and small nucleolar RNA 202 (sno202) were used as positive controls, and did not show any significant differences between wt, mdx and tg serum, whereas miR-302, which specifically expressed in embryonic stem cell, did not detect in all of sera (S1A Fig). In addition, we previously showed that the levels of myomiRs in EVs and EV-depleted supernatant fractions from the sera of DMD patients were significantly increased compared with that of healthy controls [25]. To determine the levels of the three myomiRs in the two fractions from the sera of tg, mdx, and wt mice, sera were separated by centrifugation followed by miRNA extraction. qRT-PCR demonstrated that the levels of the three myomiRs in these fractions were significantly downregulated in tg mice compared with mdx mice, in which the expression levels of the three myomiRs were significantly increased compared with wt mice (Fig 1A). To analyze the contents of the EVs in the sera of tg, mdx, and wt mice, EVs were isolated from the sera by centrifugation, and then quantified by AChE activity and EV markers. The amount of EVs, which was verified by exosomal marker proteins (S2A Fig), in the sera of mdx and tg mice at 7 weeks of age was significantly increased compared with that of wt mice; however, at 13 and 27
weeks of age, there were no significant differences in the amount of EVs between the mice (Fig 1B, left, S2B and S2C Fig). In addition, DMD patients demonstrated significantly greater amounts of EVs compared with healthy controls (Fig 1B, right). Furthermore, to characterize EV markers associated with increases in these miRNA levels, we performed immunoprecipitation assays using five antibodies and EVs from the sera of DMD patients and healthy controls. Levels of three miRNAs (miR-1, miR-133a, and miR-206 levels) and of two miRNAs (miR-1 and miR-133a) were found to be significantly enriched in CD63- and MHC II-associated EVs, respectively, in the serum of DMD patients compared with that of healthy controls (Fig 1C–1E). miR-16 were used as ubiquitous-expressed marker (S3A Fig). Similarly, to identify EV markers in mice, immunoprecipitation was performed using the five antibodies and sera from wt, mdx, and tg mice. The levels of the three myomiRs were significantly increased in CD63-associated EVs of mdx mice compared with wt mice, whereas the levels in tg mice were significantly decreased compared with mdx mice (S3B Fig). Furthermore, levels of miR-133a and miR-206 were significantly increased in EVs associated with CD81, flotillin-1, and MHC II, and flotillin-1 and MHC II, respectively, in mdx mice compared with wt mice (S3B Fig). In addition, miR-128, which expressed specifically in brain, did not detecte in EVs associated with caveolin-3 in wt mice, although miR-128 in other all of EVs were detected (S3B Fig). Ubiquitously expressed miR-16, miR-21, and miR-212 were used as positive controls, and did not show any significant differences between wt, mdx and tg serum, whereas miR-122a and miR-323 which expressed specifically in liver and brain, respectively, and miR-302 did not

Fig 1. Levels of myomiRs and EVs in the sera of DMD patients and mdx mice. (A) Levels of miR-1, miR-133a, and miR-206 in EVs-containing and EV-depleted supernatants, separated from the sera of wt, mdx, and tg mice (7-weeks old, n = 3, 4, and 4, respectively). Data are represented as means + S.E. *: P < 0.05, **: P < 0.01 for mdx vs wt or mdx vs tg. (B) EVs were extracted and quantified by AChE activity from the sera of wt, mdx, and tg mice at 7, 13, and 27 weeks of age (n = 3, 4, and 4, respectively). *: P < 0.05, **: P < 0.01 vs wt) (left) and DMD patients and healthy controls (right), (n = 5 and 4, respectively, *: P < 0.05). (C-E) miR-1 (C), miR-133a (D), and miR-206 (E) levels in EVs separated by immunoprecipitation with anti-caveolin-3 (cav3), anti-CD63, anti-CD81, anti-flotillin-1 (flot1), or anti-MHC class II (MHC II) antibodies in the sera of DMD patients and controls (n = 5 and 4, respectively). *: P < 0.05 vs controls.

doi:10.1371/journal.pone.0167811.g001
detect in all of EVs (S3B Fig). These results suggest that an increase in the levels of myomiRs in EVs may be associated with muscle degeneration.

**Ceramide metabolic pathways control EV secretion from C2C12 cells by intracellular calcium-dependent mechanisms**

Growing lines of evidence have indicated that exosome secretion is regulated by the ceramide synthesizing enzymes nSMase2/Smpd3 or the ceramide-related metabolite, Sphingosine-1-phosphate (S1P) [32, 38]. To assess whether ceramide and S1P control EV secretion in C2C12 myoblast cells, EVs, confirmed with exosomal protein markers by flow cytometry (S4A Fig) and western blot (S4B Fig), were extracted from the medium of C2C12 cells cultured with or without the nSMase inhibitor GW4869, and quantified by AChE activity. EV content was significantly decreased by treatment with GW4869 (8 μM) treatment (Fig 2A, \( P < 0.01 \)). In contrast, treatment with C2- or C6-ceramides significantly increased EV release from C2C12 myoblast cells (Fig 2B–2D), and mitigated the inhibitory effect of EV release by GW4869 (Fig 2C and 2D, \( P < 0.001 \) and \( P < 0.001 \), respectively). Moreover, ebselen, which acts as a glutathione peroxidase mimic, significantly reduced the amount of EVs released from C2C12 myoblast cells (Fig 2E, \( P < 0.001 \)). On the other hand, the ceramidase inhibitor d-erythro-MAPP (60 μM), significantly increased EV release (Fig 2F, \( P < 0.001 \)). Furthermore, S1P (40 uM) significantly increased the release of EVs from C2C12 myoblast cells (Fig 2G, \( P < 0.001 \)), and ameliorated the inhibitory effect of GW4869 (Fig 2G, \( P < 0.001 \)). These findings taken together suggested that EV release from C2C12 myoblast cells can be regulated by ceramide metabolism (Fig 2H).

Furthermore, exosome release in some cell types is also known to be regulated by a calcium-dependent mechanism [39–41]. We therefore hypothesized that intracellular calcium also regulates EV secretion in C2C12 myoblast cells. To test this hypothesis, EVs released from C2C12 myoblast cells incubated with or without the calcium ionophores monensin and A23187 were quantified by AChE activity. These two calcium ionophores significantly ameliorated the inhibitory effect of GW4869 on EV release from C2C12 cells (S5A and S5B Fig, \( P < 0.001 \), \( P < 0.01 \), respectively). Furthermore, a decrease in EV release by GW4869 was restored by caffeine, a ryanodine receptor activator (S5C Fig). However, the increase in EV release from C2C12 myoblast cells by d-erythro-MAPP was significantly recovered in the presence of the calcium-chelating agents BAPTA and EGTA (S5D and S5E Fig), or 2-APB, an inhibitor of the inositol 1,4,5-trisphosphate, the InsP3 receptor, and transient receptor potential channels (S5F Fig, \( P < 0.001 \)). Furthermore, increases in EV release by S1P were significantly decreased in the presence of EGTA (S5G Fig, \( P < 0.001 \)). Loperamide, a calcium release-activated channel activator, and cyclopiazonic acid, a sarcoendoplasmic reticulum calcium transport ATPase inhibitor, significantly increased EV release from C2C12 myoblast cells (S5H and S5I Fig, \( P < 0.001 \) for each). Taken together, these results indicate that EV release is regulated by intracellular calcium-dependent mechanisms in C2C12 myoblast cells (S5J Fig).

**Effects of EVs on C2C12 cell survival**

Exosomes released from myotubes have been reported to regulate myoblast proliferation and differentiation through intercellular crosstalk [42, 43]. However, the roles of EVs in the muscle degeneration of DMD patients remains to be clarified. To address this issue, C2C12 cells were incubated in serum-depleted medium with a low (0.7 μg), medium (2 μg), or high (7 μg) concentration of EVs extracted from the serum of mdx mice. The survival of myoblasts incubated for 24 hr with a high or medium concentration of EVs extracted from the serum was significantly increased compared with cells incubated without EVs (Fig 3A left, \( P < 0.001 \),...
respectively). In addition, the number of myotube cells incubated with a high concentration of EVs for 48 and 72 hrs was significantly increased compared with cells incubated without EVs (Fig 3A right, $P < 0.001$ and $P < 0.05$, respectively). Furthermore, the survival of myoblast cells incubated with a medium or high concentration of EVs extracted from C2C12 culture medium for 24 hrs was significantly increased compared with that without EVs (S6A Fig left, $P < 0.05$ and $P < 0.001$, respectively). Significant increases in the survival of myotube cells were observed upon incubation with a high concentration of EVs extracted from C2C12 culture medium for 48 or 72 hrs (S6A Fig right, $P < 0.001$ and $P < 0.05$, respectively). Furthermore, to determine whether EVs regulate the survival of C2C12 cells in response to apoptosis-associated stress, myoblasts were incubated with EVs from the serum of mice (Fig 3B and 3C) in one of three types of media; with H$_2$O$_2$, with ethanol, or with actinomycin D. In myoblasts and myotubes, the survival of cells incubated with a high concentration of EVs from the serum of mice was significantly increased in the presence of H$_2$O$_2$ (Fig 3B and 3C). The uptake of EVs and the mobility of the internalized EVs were reduced by the membrane cholesterol depletion regent methyl-$eta$-cyclodextrin (M$eta$CD), the microtubule polymerization inhibitors, nocodazole and simvastatin, or the MAPK inhibitor U0126 [44]. Increases in the survival of myotubes incubated with EVs from the serum of mice were significantly reversed by the treatment with M$eta$CD, nocodazole, simvastatin, or U0126 (S6B–S6D Fig).
Effect of myomiRs via EVs on the survival of C2C12 myoblasts and myotubes

Next, to analyze the effect of myomiRs via EVs on cell survival, we performed gain-of-function experiments of miR-1, miR-133a, and miR-206, which were upregulated within EVs during the differentiation of C2C12 cells (S7 Fig), using C2C12 cells and EVs extracted from C2C12 cells transfected with each miRNA (Fig 4A, S8 Fig). The survival of myoblasts incubated with EVs (6 μg) extracted from the culture medium of C2C12 cells transfected with miR-133a was significantly increased compared with those of cells transfected with miR-1 or miR-206, or untransfected cells in serum-depleted medium (S9A Fig, P< 0.05). In the presence of H2O2, the cell...
survival of myotubes incubated with EVs containing a large amount of miR-133a was significantly increased compared with cells incubated with EVs prepared from untransfected C2C12 cells (non-TF EVs) (S9B Fig, \( P < 0.05 \)). All of the C2C12 myotubes cultured with EVs (7 \( \mu \)g) from cells transfected with miR1, miR-133a, or miR-206 demonstrated significantly increased survival compared with cells cultured without EVs in serum-depleted medium for 48 and 72 hr (Fig 4B, \( P < 0.001 \)). Furthermore, we compared the survival of cells treated with two types of EVs, namely, EVs-133a and EVs-non-133a, which are EVs from C2C12 cells transfected with and without miR-133a, respectively. The cell survival of C2C12 myotubes cultured with EVs-133a from medium of C2C12 cells transfected with miR-133a, miR-1/miR-133a, miR-133a/miR-206, or miR-1/miR-133a/miR-206 were significantly increased compared with EVs-non-133a from cells transfected with miR-1, miR-206, or nontransfected cells in serum-depleted medium for 72 hours (Fig 4B, \( P < 0.001 \)), but not for 24 and 48 hours (Fig 4B). No significant differences were observed in C2C12 myotubes cultured with EVs from cells transfected with miR-1, miR-206, or nontransfected cells (Fig 4B). Furthermore, the numbers of C2C12 myotubes cultured with low (0.8 \( \mu \)g) or medium (2.0 \( \mu \)g) concentrations of EVs were significantly increased compared with that without EVs for 72 hr (S10A and S10B Fig, \( P < 0.05 \) and \( P < 0.001 \), respectively). However, no significant differences were observed in the cell survival of C2C12 myoblasts cultured with EVs-

![Diagram](image-url)
133a or EVs-non-133a for 48 or 72 hrs (data not shown). These results suggest that the survival of myotubes may be partially regulated by miR-133a via EVs.

**Effect of miR-133a via EVs on the expression of genes associated with apoptosis and differentiation in C2C12 cells**

We next investigated whether the effect miR-133a via EVs on the survival of myotubes was regulated by its target genes directly or indirectly through the targeting functions of miRNA. To test this hypothesis, we quantified the expression levels of putative target genes in C2C12 cells cultured with or without EVs containing a large amount of miR-133a. qRT-PCR demonstrated that the levels of miR-133a were significantly upregulated by the incubation of cells with the EVs (Fig 5A). Furthermore, the levels of bcl-2, caspase-9, myoG, and srf transcripts were significantly decreased by the incubation of cells with these EVs (Fig 5B, left). Whereas the expression level of myh1 was significantly upregulated by the incubation of cells with these EVs, cycd1 was not changed (Fig 5B, right). Moreover, caspase-3 activity in C2C12 cells cultured with EVs in the presence of H2O2 was significantly decreased compared with that without EVs (Fig 5C). These findings indicated that the protective effects against apoptosis of C2C12 cells by EVs might be in part controlled by regulation of the expression of genes targeted by miR-133a.

**Inhibition of ceramide synthesis ameliorates muscular dystrophy in mdx mice**

To further investigate whether myomiRs improve muscular dystrophy in mdx mice, GW4869 (100 μM) was intraperitoneally administered into mdx mice for 5 or 10 days (Fig 6A). After the administration of GW4869, the levels of miR-1, miR-133a, and miR-206, as well as the level of CK, which is indicative of sarcolemmal leakage, were quantified. The levels of myomiRs in the serum (Fig 6B), serum-derived EVs (S11A Fig), and the EV-depleted serum supernatant (S11B Fig) of mdx mice treated with GW4869 were significantly decreased compared with that of the controls. Furthermore, serum CK levels of mdx mice treated with GW4869 for 5 and 10 days were also significantly decreased compared with those of controls (Fig 6C, P < 0.05 and P < 0.01, respectively). The tibialis anterior muscle of GW4869-injected mdx mice showed a significant decrease in the area of uptake of EBD, which accumulates in damaged cells, compared with that of control mdx mice (Fig 6D, top and Fig 6E). On the other hand, only a slight, but insignificant decrease in EBD uptake was observed in the diaphragm of mdx mice injected with GW4869 compared with that of the controls (Fig 6D, bottom and Fig 6E). To test the improvement of myofiber structure and function upon GW4869 injection, we analyzed the expression of utrophin in the TA muscle of mdx mice treated with GW4869 for 10 days, as well as in untreated mdx mice. However, utrophin protein levels in GW4869-treated mice were not increased compared to those of controls (S12 Fig). These results suggested that the inhibition of ceramide synthesis leads to the suppression of EV secretion, which may affect the level of muscular dystrophy in mdx mice.

**Discussion**

The present study showed that myomiRs are noninvasive biomarkers for the diagnosis of DMD, and that the regulation of myomiR levels may possibly be established as a novel therapy for DMD. We found significant decreases in the levels of miR-1, miR-133a, and miR-206 in the serum of tg mice (mdx mice overexpressing a truncated dystrophin protein showing normal muscle activities) compared with those of mdx mice at 7 weeks of age. Moreover, Roberts et al. reported that restoration of the dystrophin protein by the skipping of exon 23 from the
mature dystrophin transcript partially normalized serum myomiRs levels [26]. Furthermore, we previously demonstrated that the upregulation of myomiRs levels in the sera of mice occurred transiently upon CTX-induced injury of their TA one day after the injury [25]. These data suggested that an increase in serum myomiR levels might be dependent on muscle degeneration.

Next, we presented evidence that the secretion of EVs from C2C12 cells was regulated by sphingolipids metabolism. In agreement with a previous report [45], our study demonstrated significant increases in the secretion of EVs into the extracellular space in the sera of young DMD patients or mdx mice compared with controls. However, difference of serum myomiRs level in exosome and exosome-depleted supernatant fractions between our study and previously published data was observed [45]. The two studies were differences for extraction method of exosomes and RNAs from mice serum, and its serum volume as the starting materials. It was reported the difference of number of extracellular vesicles extracted using by Total exosome isolation regent and ultracentrifugation method, although these particle size distributions isolated by the two methods showed no differences and exhibited similar size distribution for exosome, that is a mean diameter of 70–80 nm [46]. Moreover, it was previously reported that the amount of total RNA recovered from exosomes using by Total exosome isolation regent and ultracentrifugation method, although these particle size distributions isolated by the two methods showed no differences and exhibited similar size distribution for exosome, that is a mean diameter of 70–80 nm [46].

Fig 5. Effect of miRNAs in EVs on C2C12 cell gene expression. (A) Myotubes were incubated for 72 hr with 1.0 or 2.0 μg of EVs extracted from C2C12 cells. Total RNA was extracted from the myotubes. Levels of miR-133a (A) and relative mRNA levels of putative target genes (B) were measured by RT-quantitative PCR. (C) Caspase-3 activity was measured in lysates of C2C12 myotube cells cultured with EVs (4 μg) for 24 hr. Data represent mean ± S.E. *: P < 0.05, **: P < 0.01, ***: P < 0.001 versus the relevant control.

doi:10.1371/journal.pone.0167811.g005
factor-β, or tumor necrosis factor-α (TNF-α) [24]. Furthermore, nSMase2/Smpd3 is activated by TNF-α-stimulated p38 MAPK [49, 50], and preferentially traffics to the plasma membrane upon exposure to an oxidant, such as H₂O₂, and is inhibited by the antioxidant, glutathione-SH (GSH) [51, 52]. Thus, the release of EVs into the extracellular space in DMD patients might be induced by the activation of nSMase2/Smpd3, following ceramide production mainly from sphingomyelin in response to some types of cellular stimulation.

In this study, miR-133a in EVs exerted protective effects against C₂C₁₂ cell stress, via the suppression of the expression of apoptosis-associated genes, despite the EVs including various bioactive molecules, such as mRNA, protein, and DNA. It was reported that the overexpression of these myomiRs had little effect on the proliferation or apoptosis of cardiac progenitor...
cells (CPCs) under basal conditions, whereas miR-133a increased cell survival under oxidative stress in part through targeting of the potent proapoptotic factors, \textit{Bim} and \textit{Bmf} [53]. In addition, overexpression of miR-133a in the skeletal muscle of mice did not result in any overt muscle defects [54]. In our study, \textit{C2C12} cells cultured with EVs in growth medium did not exhibit a significant difference in survival compared with untreated control cells (data not shown). These findings indicate that miR-133a within EVs in the absence of cellular stresses may not affect muscle survival.

In addition, some previous reports indicated that caspase-9 is a possible direct target of miR-133a, and the inhibition of miR-133a increases caspase-9 and caspase-3 activity as well as the number of apoptotic cells in cardiomyocytes [53, 55–57]. Expression levels of caspase-3, caspase-9, and \textit{Bax} expression levels have been shown to be significantly upregulated in the muscle of \textit{mdx} mice [58]. An imbalance between the production and degeneration of myocytes, exacerbated by increased apoptosis and decreased regenerative capacity leads to atrophy in the skeletal muscle of \textit{mdx} mice [59]. Moreover, it was reported that miR-133a is a direct target for apoptotic protease-activating factor 1 and has a protective effect on apoptosis by repressing the expression of apoptotic genes [60]. Moreover, miR-133a attenuates hypoxia-induced apoptosis by suppressing caspase-8 signals via its inhibition of the \textit{TAGLN2} gene in cardiomyocytes [61]. It was recently demonstrated that miR-133a inhibits injury-induced cardiomyocyte apoptosis by targeting the \textit{DAPK2} gene [62]. In our study, caspase-3 activity was decreased by miR-133a via EVs in \textit{C2C12} cells under conditions of cell stress. These findings indicate that modification of apoptosis by miR-133a might be a novel therapeutic strategy for DMD.

Expression of the inositol 1,4,5-triphosphate receptor II (IP3RII) calcium channel was constitutively suppressed by miR-133a [55]. In cardiomyocytes, the inhibitory action of miR-133a maintains low basal IP3RII expression. The decline in miR-133a levels resulted in the upregulation of Ca$^{2+}$ levels. In the present study, it was shown that the secretion of EVs from \textit{C2C12} cells may be modulated by intracellular Ca$^{2+}$ concentrations. A chronic increase in Ca$^{2+}$ concentrations in skeletal muscles fibers of DMD patients and \textit{mdx} mice has been observed [63–65]. These reports suggest that the secretion of EVs may be regulated by increases in intracellular Ca$^{2+}$ concentrations, which is induced by IP3RII targeting by miR-133a.

Treatment of \textit{mdx} mice with GW4869 resulted in a significant decrease in myomiR levels in the serum compared with untreated \textit{mdx} mice. In addition, myomiR levels in both EV-containing and EV-depleted supernatant fractions from the sera of GW4869-treated \textit{mdx} mice were significantly lower than in untreated \textit{mdx} mice. It was reported that the local injection of myomiRs or exosomes enhanced muscle regeneration and prevented fibrosis via the expression of myogenic factors in skeletal muscle of injured rat and mouse models [44, 66]. Exosomes extracted from differentiating human myoblasts include various growth factors, such as basic FGF, hepatocyte growth factor, insulin like growth factors-I, and vascular endothelial growth factor receptor, which are significantly upregulated in miR-133a-overexpressed adult mouse CPCs [43, 53]. Taking these findings together, the transfer of myomiRs via exosomes may play a role in muscle regeneration, although we cannot exclude the possibility of their beneficial effects on skeletal muscle repair via ceramide or its metabolites.

In summary, our study demonstrated that the release of myomiRs into the blood circulation was associated with the degeneration of skeletal muscle. The secretion of EVs may be regulated by ceramide metabolism by \textit{Smpd3} in \textit{C2C12} cells. Moreover, the transport of miR-133a via EVs into \textit{C2C12} cells increases cell survival under conditions of cellular stress. The inhibition of ceramide synthesis resulted in the suppression of EV secretion, and improved muscle dystrophy in \textit{mdx} mice. Taken together, these findings suggest that EV-mediated myomiR delivery may have potential as a cell-free therapeutic strategy for DMD, by enabling intracellular communication.
Supporting Information

S1 Fig. Levels of myomiRs in the sera of *mdx* mice. (A) Levels of miR-1, miR-133a, and miR-206 in the sera of wt, *mdx*, and *tg* mice (7-weeks old, n = 3, 4, and 4, respectively). miR-21, miR-29, and sno202 are used as ubiquitous-expressed miRNAs. miR-302 is specifically expressed in embryonic stem cell. Data are represented as means + S.E. *: P < 0.05, **: P < 0.01, ***: P < 0.001 for *mdx* vs wt or *mdx* vs *tg*. (TIFF)

S2 Fig. Contents of the EVs from serum. (A) Western blots of exosomes isolated from 200 μL of serum from 5-week old *mdx* mice using antibodies of the exosome markers, CD63, CD9, caveolin-3, and MHC class II. HSP90, apoA-I, and calnexin was used as a positive or negative control for cell lysate from SHSY-5Y cells (cell lysate), exosome and exosome-depleted supernatant (sup). (B) Western blot of Lam2, exosome marker, using 50 μL of serum from 5-weeks old *mdx* or wt mice using antibody against the exosome marker Lamp2. Transferrin was used as a positive control. (C) EV content in the sera of wt, *mdx*, and *tg* mice. EVs were extracted from the sera of wt, *mdx*, and *tg* mice (7, 13, and 27-weeks old) by using Total Exosome Isolation kit. Ten μg/μL of EVs were serially diluted in PBS. One μL of EV solutions (10, 5, 2.5, 1.25, 0.63, and 0.31 μg/μL) were subjected to dot blot analysis using anti-MHC class II and anti-CD63 antibodies. (TIFF)

S3 Fig. Levels of miRNAs in EVs. (A) miR-16 level in the EVs separated by immunoprecipitation with anti-caveolin-3 (Cav3), anti-CD63, anti-CD81, anti-flotillin-1 (Flot1), or anti-MHC class II (MHC II) antibodies from the sera of DMD patients and controls (n = 5 and 4, respectively). (B) miR-1, miR-133a, or miR-206 levels in the EVs separated by immunoprecipitation with anti-caveolin-3, anti-CD63, anti-CD81, anti-flotillin-1, or anti-MHC class II antibodies from the sera of wt, *mdx*, and *tg* mice (7-weeks old, n = 3, 4, and 4, respectively). miR-16, miR-21, and miR-212 were used as ubiquitous-expressed miRNAs. miR-122a and miR-323 are specifically expressed in liver and brain, respectively. Data are represented as means + S.E. *: P < 0.05, **: P < 0.01, ***: P < 0.001 for *mdx* vs wt or *mdx* vs *tg*. (TIFF)

S4 Fig. Measurement of the surface expression of caveolin-3, CD9, and CD81 on EVs extracted from the medium of C2C12 culture cells. (A) EVs covalently bound by aldehyde/sulfate latex beads were mixed with antibodies against caveolin-3, CD9, and CD81, followed by the anti-rat IgG Alexa 488 secondary antibody, and then subjected to flow cytometry analysis. (left) Gating was performed to define area containing EVs, and percentages are indicated. (right) Representative flow cytometric histograms showing caveolin-3, CD9, and CD81-labeled exosome-bead complexes, with percentages indicated for each subpopulation. Staining without secondary antibody was used as a negative control. (B) Western blot analysis of cell lysate and exosomes from C2C12 myoblast cells using by Total Exosome Isolation Reagent with anti-CD63, anti-caveolin-3, anti-flotillin-1, anti-GAPDH, anti-HSP90, and anti-calnexin antibodies. (TIFF)

S5 Fig. Effects of calcium on the secretion of exosomes from C2C12 myoblasts. (A–F) C2C12 cells (90% confluent) were incubated for 24 hr with GW4869 and monensin (A), GW4869 and A23187 (B), or GW4869 and caffeine (C), D-erythro-MAPP and BAPTA (D), D-erythro-MAPP and EGTA (E), or D-erythro-MAPP and 2-APB (F) in serum-depleted medium. (G–I) C2C12 cells (90% confluent) were incubated for 24 hr with S1P and EGTA (G), loperamide
(H), and cyclopiazonic acid (I) in serum-depleted medium. (J) Schematic figure of the effects of calcium on exosome release. CRAC: calcium release-activated channels; Rab: Rab GTPase activating protein; SERCA: sarco/endoplasmic reticulum Ca\(^{2+}\)-ATPase; RyR: ryanodine receptor; InsP3R: Inositol trisphosphate receptor. The amounts of released exosomes were quantified by measuring AChE activities. Data represent means ± S.E. of absorbance at 405 nm. *: \(P < 0.05\), **: \(P < 0.01\), ***: \(P < 0.001\).

(TIFF)

S6 Fig. Effect of EVs on C\(_2\)C\(_{12}\) cell survival. (A) C\(_2\)C\(_{12}\) myoblasts (left) and myotubes (right) were differentiated for 3 days and then incubated for the indicted times in serum-depleted medium with low (0.7 \(\mu\)g), medium (2 \(\mu\)g), or high (6 \(\mu\)g) concentrations of EVs that were extracted from C\(_2\)C\(_{12}\) culture medium. (B-D) C\(_2\)C\(_{12}\) myoblasts were differentiated for 2 days in 2% serum-containing DMEM, followed by incubation with/without EVs (2 \(\mu\)g) extracted from mouse serum, in serum-free medium with or without 1.0 mM (+) or 2.0 mM (++) of methyl-\(\beta\)-cyclodextrin (M\(\beta\)CD) for 48 hr (B), or 20 mg/mL of nocodazole (Nocod.) or 2 mM of Simvastatin (Simv.) for 48 hr (C), or 500 mM of U0126 for 24 hr (D). Data are represented as mean ± S.D. for absorbance at 450 nm by CCK-8. *: \(P < 0.05\), **: \(P < 0.01\), ***: \(P < 0.001\).

(TIFF)

S7 Fig. miR-1, miR-133a, and miR-206 levels within EVs extracted from the culture medium of C\(_2\)C\(_{12}\) cells at different stages of differentiation. C\(_2\)C\(_{12}\) cells were cultured with growth medium until 90% confluency and then changed to differentiation medium for 1 to 6 days. miRNAs were isolated from EVs extracted from the media of C\(_2\)C\(_{12}\) cells on the indicated days and miR-1, miR-133a, and miR-206 levels were measured by RT-quantitative PCR.

(TIFF)

S8 Fig. myomiR levels within EVs extracted from C\(_2\)C\(_{12}\) cells transfected with each myomiR. miR-1, miR-133a, and miR-206 levels within EVs extracted from the medium of C\(_2\)C\(_{12}\) cells transfected with miR-1, miR-133a, or miR-206, and their four possible combinations (miR-1/miR-133a, miR-1/miR-206, miR-133a/miR-206, and miR1/miR-133a/miR-206) were measured by RT-quantitative PCR. Levels are shown relative to that of the non-transfected cells, which was set to 1.

(TIFF)

S9 Fig. Survival of myoblasts and myotubes upon incubation with EVs. Myoblasts (A) and myotubes (B), differentiated for 4 days, were incubated with or without low (0.7 \(\mu\)g), medium (2 \(\mu\)g), or high (6 \(\mu\)g) concentrations of EVs extracted from the medium of C\(_2\)C\(_{12}\) cells transfected with miR-1, miR-133a, or miR-206, or non-transfected (non-TF EVs) for 24 hrs in serum-depleted medium (A) or in the presence of H\(_2\)O\(_2\) (10 mM) (B). Data represent mean ± S.E. *: \(P < 0.05\).

(TIFF)

S10 Fig. Effect of miRNAs within EVs on C\(_2\)C\(_{12}\) myotubes survival. Myotubes were incubated in serum-depleted medium, with 0.8 \(\mu\)g (A), 2 \(\mu\)g (B) of EVs extracted from the medium of C\(_2\)C\(_{12}\) cells transfected with miR-1, miR-133a, miR-206, or their four possible combinations (miR-1/miR-133a, miR-1/miR-206, miR-133a/miR-206, and miR1/miR-133a/miR-206) for the indicated times. Data are represented as mean ± S.D. for absorbance at 450 nm by CCK-8. *: \(P < 0.05\), ***: \(P < 0.001\).

(TIFF)

S11 Fig. myomiRs levels within EVs or EV-depleted supernatants. miR-1, miR-133a, and miR-206 levels in EVs (A), or EV-depleted supernatants (B) from sera of untreated control
mdx (mdx), GW4869-treated mdx for 5 days (GW4869-5d), GW4869-treated mdx for 10 days (GW4869-10d), and wt mice were measured by RT-quantitative PCR. Data represent mean + S.E. *: P < 0.05, **: P < 0.01, ***: P < 0.001.

S12 Fig. Expression of utrophin in TA muscle. TA muscle lysates of mdx mice treated with GW4869 for 10 days or untreated control mdx mice were subjected to western blotting to analyze utrophin expression. Gapdh (Glyceraldehyde 3-phosphate dehydrogenase) and tublin were used as loading controls.

S13 Fig. Secondary structure of the myomiRs, miR-1 (A), miR-133a (B), and miR-206 (C) based on ΔG values.

S1 Table. Secondary structure of myomiRs. GC contents and ΔG for mature sequences of myomiRs were estimated.

Acknowledgments
We thank Drs. Satoru Noguchi (National Center of Neurology and Psychiatry) and Naoki Ito (National Center of Neurology and Psychiatry) for kindly providing the C2C12 cells, Dr. Wataru Araki (National Center of Neurology and Psychiatry) for kindly providing the SHSY-5Y cells, and Mr. Satoru Masuda for technical supports with flow cytometry. This study was supported by Intramural Research Grant (25–5) for Neurological and Psychiatric Disorders of NCNP.

Author Contributions
Conceptualization: YM JT ST KH.
Data curation: YM JT UR ST KH.
Formal analysis: YM JT KH.
Funding acquisition: ST KH.
Investigation: YM JT ST KH.
Methodology: YM JT ST KH.
Project administration: ST KH.
Resources: YM JT HK AI YO ST KH.
Software: YM JT KH.
Supervision: ST KH.
Validation: YM JT UR ST KH.
Visualization: YM JT KH.
Writing – original draft: YM JT UR KH.
Writing – review & editing: YM UR KH.
References

1. Durbeej M, Campbell KP. Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models. Curr Opin Genet Dev. 2002; 12:349–361. PMID: 12076680

2. Takeshima Y, Yagi M, Okizuka Y, Awano H, Zhang Z, Yamauchi Y, et al. Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center. J Hum Genet. 2010; 55:379–388. doi: 10.1038/jhg.2010.48 PMID: 20465447

3. Sultan A, Fayaz M. Prevalence of cardiomyopathy in Duchenne and Becker’s muscular dystrophy. J Ayub Med Coll Abbottabad. 2008; 20(2):7–13. PMID: 19385447

4. Malm C, Sjödin TL, Sjöberg B, Lenkei R, Renström P, Lundberg I, et al. Leukocytes, cytokines, growth factors and hormones in human skeletal muscle and blood after uphill or downhill running. J Physiol. 2004; 556:983–1000. doi: 10.1113/jphysiol.2003.056598 PMID: 14766942

5. Zatz M, Rapaport D, Vainzof M, Passos-Bueno MR, Bortolini ER, Pavanello Rde C, et al. Serum creatine-kinase (CK) and pyruvate-kinase (PK) activities in Duchenne (DMD) as compared with Becker (BMD) muscular dystrophy. J Neurol Sci. 1991; 102(2):190–196. PMID: 2072118

6. Lee S, Vasudevan S. Post-transcriptional stimulation of gene expression by microRNAs. Adv Exp Med Biol. 2013; 768:97–126. doi: 10.1007/978-1-4614-5107-5_7 PMID: 23224967

7. Ørom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell. 2008; 30:460–471. doi: 10.1016/j.molcel.2008.05.001 PMID: 18498749

8. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010; 11(9):597–610. doi: 10.1038/nrg2843 PMID: 20661255

9. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. J Physiol. 2011; 556:983–1000. doi: 10.1113/jphysiol.2010.056598 PMID: 21383194

10. Vickers KC, Palmisano BT, Shoucri BM, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011; 13(4):423–433. doi: 10.1038/ncb2210 PMID: 21423178

11. Wang K, Zhang S, Weber J, Baxter D, Galas DJ. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res. 2010; 38(20):7248–7259. doi: 10.1093/nar/gkq601 PMID: 20615901

12. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9(6):654–659. doi: 10.1038/ncto2007-00100 PMID: 17486113

13. Skog J, Würdinger T, van Rijn S, Meijer DH, Sena-Esteves M, Curry WT Jr, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10(12):1470–1476. doi: 10.1038/ncb1800 PMID: 19011622

14. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal. 2009; 2(100):ra81. doi: 10.1126/scisignal.2000610 PMID: 19996457

15. Pestel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA, Hopmans ES, Lindenberg JL, et al. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci U S A. 2010; 107(14):6328–6333. doi: 10.1073/pnas.0909482107 PMID: 20304794

16. Ratajczak J, Miekus K, Kucia M, Zhang J, Reca R, Dvorak P, et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia. 2006; 20(5):847–856. doi: 10.1038/sj.leu.2404132 PMID: 16453000

17. Deregibus MC, Cantaluppi V, Calogero R, Lo Iacono M, Tetta C, Biancone L, et al. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood. 2007; 110(7):2440–2448. doi: 10.1182/blood-2007-03-078709 PMID: 17536014

18. Zhu H, Fan GC. Extracellular/circulating microRNAs and their potential role in cardiovascular disease. Am J Cardiovasc Dis. 2011; 1:138–149. PMID: 22059153

19. Hu G, Drescher KM, Chen XM. Exosomal microRNAs: Biological Properties and Therapeutic Potential. Front Genet. 2012; 3:56. doi: 10.3389/fgene.2012.00056 PMID: 22529849

20. Ge Q, Zhou Y, Lu J, Bai Y, Xie X, Lu Z. miRNA in plasma exosome is stable under different storage conditions. Molecules. 2014; 19(2):1568–1575. doi: 10.3390/molecules19021568 PMID: 24473212
22. Cacchiarelli D, Legnini I, Martone J, Cazzella V, D’Amico A, Bertini E, et al. miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Mol Med. 2011; 3:258–265. doi: 10.1002/emmm.201100133 PMID: 21452469

23. Mizuno H, Nakamura A, Aoki Y, Ito N, Kishi S, Yamamoto K, et al. Identification of muscle-specific microRNAs in serum of muscular dystrophy animal models: promising novel blood-based markers for muscular dystrophy. PLoS One. 2011; 6:e18388. doi: 10.1371/journal.pone.0018388 PMID: 21479190

24. Li X, Li Y, Zhao L, Zhang D, Yao X, Zhang H, et al. Circulating Muscle-specific miRNAs in Duchenne Muscular Dystrophy Patients. Mol Ther Nucleic Acids. 2014; 2:177.

25. Matsuzaka Y, Kishi S, Aoki Y, Komaki H, Oya Y, Takeda S, et al. Three novel serum biomarkers, miR-1, miR-133a, and miR-206 for Limb-girdle muscular dystrophy. Facioscapulohumeral muscular dystrophy, and Becker muscular dystrophy. Environ Health Prev Med. 2014; 19:452–458. doi: 10.1007/s12199-014-0405-7 PMID: 25150707

26. Roberts TC, Blomberg KE, McClorey G, El Andaloussi S, Godfrey C, Betts C, et al. Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy. Mol Ther Nucleic Acids. 2012; 14:e39.

27. Cacchiarelli D, Martone J, Girardi E, Cesana M, Incitti T, Morlando M, et al. MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dysphosphinosinopathway. Cell Metab. 2010; 12:341–351. doi: 10.1016/j.cmet.2010.07.008 PMID: 20727829

28. Cazzella V, Martone J, Pinnaró C, Santini T, Twayana SS, Shandler O, et al. Exon 45 skipping through U1-sRNA antisense molecules recovers the Dys-nNOS pathway and muscle differentiation in human DMD myoblasts. Mol Ther. 2012; 20(11):2134–2142. doi: 10.1038/mt.2012.178 PMID: 22968481

29. Güller I, Russell AP. MicroRNAs in skeletal muscle: their role and regulation in development, disease and function. J Physiol. 2010; 588:4075–4087. doi: 10.1111/j.1440-1613.2010.194175 PMID: 20724363

30. Matsuzaka Y, Hashido K. Roles of mir-1, mir-133a, and mir-206 in calcium, oxidative stress, and NO signaling involved in muscle diseases. RNA & Disease. 2015; 2:e558.

31. Kosaka N, Iuchi H, Hagiwara K, Yoshioka Y, Takeshita F, Ochiya T. Neutral sphingomyelinase 1-dependent exosomal transfer of angiogenic microRNAs regulate cancer cell metastasis. J Biol Chem. 2013; 288:10848–59. doi: 10.1074/jbc.M112.446831 PMID: 23439645

32. Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008; 319:1244–1247. doi: 10.1126/science.1153124 PMID: 18309083

33. Kubota S, Chiba M, Watanabe M, Sakamoto M, Watanabe N. Secretion of small/microRNAs including miR-638 into extracellular spaces by sphingomyelin phosphodiesterase 3. Oncol Rep. 2013; 288:10848–59. doi: 10.1074/jbc.M112.446831 PMID: 23439645

34. Singh R, Pochampally R, Watabe K, Lu Z, Mo YY. Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer. Mol Cancer. 2014; 13:256. doi: 10.1186/1476-4598-13-256 PMID: 25428807

35. Mittelbrunn M, Gutiérrez-Vázquez C, Villarroya-Beltri C, González S, Sánchez-Cabo F, González MA, et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Commun. 2011; 2:282. doi: 10.1038/ncomms1285 PMID: 21050438

36. Savina A, Furlán M, Vidal M, Colombo MI. Rab11 promotes docking and fusion of multivesicular bodies in a calcium-dependent manner. Traffic. 2005; 6(2):131–143. doi: 10.1111/j.1600-0854.2004.00257.x PMID: 15634213

37. Bodensteiner JB, Engel AG. Intracellular calcium accumulation in Duchenne dystrophy and other myopathies: a study of 567,000 muscle fibers in 114 biopsies. Neurology. 1978; 28(5):439–446. PMID: 76996

38. Kajimoto T, Okada T, Miya S, Zhang L, Nakamura S. Ongoing activation of sphingosine 1-phosphate receptors mediates maturation of exosomal multivesicular endosomes. Nat Commun. 2013; 4:2712. doi: 10.1038/ncomms3712 PMID: 24231649

39. Savina A, Furlán M, Vidal M, Colombo MI. Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J Biol Chem. 2003; 278(22):20083–20090. doi: 10.1074/jbc.M301642200 PMID: 12639953

40. Tamaki K, Tanaka N, Nakano T, Kakazu E, Kondo Y, Inoue J, et al. Exosome secretion of dendritic cells is regulated by Hrs, an ESCRT-0 protein. Biochem Biophys Res Commun. 2010; 399(3):384–90. doi: 10.1016/j.bbrc.2010.07.083 PMID: 20673754

41. Ekström EJ, Bergenfelz C, von Bülow V, Serfler F, Carlemalm E, Jönsson G, et al. WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells. Mol Cancer. 2014; 13:88. doi: 10.1186/1476-4598-13-88 PMID: 24766647
42. Forterre A, Jalabert A, Berger E, Baudet M, Chikh K, Errazuriz E, et al. Proteomic analysis of C2C12 myoblast and myotube exosome-like vesicles: a new paradigm for myoblast-myotube cross talk? PLoS One. 2014; 9:e84153. doi: 10.1371/journal.pone.0084153 PMID: 24392111

43. Choi JS, Yoon HI, Lee KS, Choi YC, Yang SH, Kim IS, et al. Exosomes from differentiating human skeletal muscle cells trigger myogenesis of stem cells and provide biochemical cues for skeletal muscle regeneration. J Control Release. 2016; 222:107–115. doi: 10.1016/j.jconrel.2015.12.018 PMID: 26699421

44. Svensson KJ, Christianson HC, Wittrup A, Bourseau-Guilmain E, Lindqvist E, Svensson LM, et al. Exosome uptake depends on ERK1/2–heat shock protein 27 signaling and lipid raft-mediated endocytosis negatively regulated by caveolin-1. J Biol Chem. 2013; 288:17713–17724. doi: 10.1074/jbc.M112.445403 PMID: 23653359

45. Roberts TC, Godfrey C, McClurey G, Vader P, Briggs D, Gardiner C, et al. Extracellular microRNAs are dynamic non-vesicular biomarkers of muscle turnover. Nucleic Acids Res. 2013; 41(20):9500–9513. doi: 10.1093/nar/gkt724 PMID: 25559219

46. Lane RE, Korbie D, Anderson W, Vaidyanathan R, Trau M. Analysis of exosome purification methods using a model liposome system and tunable-resistive pulse sensing. Sci Rep. 2015; 5:7639. doi: 10.1038/srep07639 PMID: 25559219

47. Zeringer E, Li M, Barta T, Schagamen J, Pedersen KW, Neurauter A, et al. Methods for the extraction and RNA profiling of exosomes. World J Methodol. 2013; 3(1):11–18. doi: 10.5662/wjm.v3.i1.11 PMID: 25237619

48. Kim YK, Yeo J, Kim B, Ha M, Kim VN. Short structured RNAs with low GC content are selectively lost during extraction from a small number of cells. Mol Cell. 2012; 46(6):893–895. doi: 10.1016/j.molcel.2012.05.036 PMID: 22749402

49. Clarke CJ, Truong TG, Hannun YA. Role for neutral sphingomyelase-2 in tumor necrosis factor alpha-stimulated expression of vascular cell adhesion molecule-1 (VCAM) and intercellular adhesion molecule-1 (ICAM) in lung epithelial cells: p38 MAPK is an upstream regulator of nSMase2. J Biol Chem. 2007; 282:1394–1396. doi: 10.1074/jbc.M609216200 PMID: 17085432

50. Shamseddine AA, Airola MV, Hannun YA. Roles and regulation of neutral sphingomyelinase-2 in cellular and pathological processes. Adv Biol Regul. 2015; 57:24–41. doi: 10.1016/j.jbior.2014.10.002 PMID: 25465297

51. Levy M, Castillo SS, Goldberg T. nSMase2 activation and trafficking are modulated by oxidative stress to induce apoptosis. Biochem Biophys Res Commun. 2006; 344:900–905. doi: 10.1016/j.bbrc.2006.06.025 PMID: 16631623

52. Clarke CJ, Hannun YA. Neutral sphingomyelinas and nSMase2: bridging the gaps. Biochim Biophys Acta. 2006; 1758:1893–1901. doi: 10.1016/j.bbamem.2006.06.025 PMID: 16938269

53. Izarra A, Moscoso I, Levent E, Cañon S, Cerrada I, Díez-Juan A, et al. miR-133a enhances the protective capacity of cardiac progenitor cells after myocardial infarction. Stem Cell Reports. 2014; 3:1029–1042. doi: 10.1016/j.stemcr.2014.10.010 PMID: 25465869

54. Deng Z, Chen JF, Wang DZ. Transgenic overexpression of miR-133a in skeletal muscle. BMC Musculoskelet Disord. 2011; 12:115. doi: 10.1186/1471-2474-12-115 PMID: 21615921

55. Drawnel FM, Wachten D, Molkentin JD, Maillet M, Aronsen JM, Swift F, et al. Mutual antagonism between IP3R and miRNA-133a regulates calcium signals and cardiac hypertrophy. J Cell Biol. 2012; 199:783–798. doi: 10.1083/jcb.20111095 PMID: 23166348

56. He B, Xiao J, Ren AJ, Zhang YF, Zhang H, Chen M, et al. Role of miR-1 and miR-133a in myocardial ischemic postconditioning. J Biomed Sci. 2011; 18:122. doi: 10.1186/1423-0127-18-122 PMID: 21406115

57. Wang L, Li X, Zhou Y, Shi H, Xu C, He H, et al. Downregulation of miR-133 via MAPK/ERK signaling pathway involved in nicotine-induced cardiomyocyte apoptosis. Naunyn Schmiedebergs Arch Pharmacol. 2014; 387:197–206. doi: 10.1007/s00210-013-0929-1 PMID: 24190542

58. Honda A, Abe S, Hiroki E, Honda H, Iwanuma O, Yanagisawa N, et al. Activation of caspase 3, 9, 12, and Bax in masseter muscle of mdx mice during necrosis. J Muscle Res Cell Motil. 2007; 28:243–247. doi: 10.1007/s10974-007-9122-9 PMID: 17952618

59. Moussiel E, Vignaud A, Houndé C, Butler-Browne G, Ferry A. Muscle weakness and atrophy are associated with decreased regenerative capacity and changes in mTOR signaling in skeletal muscles of ven erable (18-24-month-old) dystrophic mdx mice. Muscle Nerve. 2010; 41:809–818. doi: 10.1002/mus.21624 PMID: 20151467

60. Dakhilallah D, Zhang J, Yu L, Marsh CB, Angelos MG, Khan M. MicroRNA-133a engineered mesenchymal stem cells augment cardiac function and cell survival in the infarcted heart. J Cardiovasc Pharmacol. 2015; 65(3):241–251. doi: 10.1097/FJC.0000000000001833 PMID: 25658461
61. Li AY, Yang Q, Yang K. miR-133a mediates the hypoxia-induced apoptosis by inhibiting TAGLN2 expression in cardiac myocytes. Mol Cell Biochem. 2015; 400(1–2):173–181. doi: 10.1007/s11010-014-2273-2 PMID: 25421410

62. Li S, Xiao FY, Shan PR, Su L, Chen DL, Ding JY, et al. Overexpression of microRNA-133a inhibits ischemia-reperfusion-induced cardiomyocyte apoptosis by targeting DAPK2. J Hum Genet. 2015; 60(11):709–716. doi: 10.1038/jhg.2015.96 PMID: 26334104

63. Mallouk N, Jacquemond V, Allard B. Elevated subsarcolemmal Ca2+ in mdx mouse skeletal muscle fibers detected with Ca2+-activated K+ channels. Proc Natl Acad Sci U S A. 2000; 97(9):4950–4955. PMID: 10781103

64. Robert V, Massimino ML, Tosello V, Marsault R, Cantini M, Sorrentino V, et al. Alteration in calcium handling at the subcellular level in mdx myotubes. J Biol Chem. 2001; 276(7):4647–4651. doi: 10.1074/jbc.M006337200 PMID: 11029464

65. Vandebrouck C, Martin D, Colson-Van Schoor M, Debaix H, Gailly P. Involvement of TRPC in the abnormal calcium influx observed in dystrophic (mdx) mouse skeletal muscle fibers. J Cell Biol. 2002; 158(6):1089–1096. doi: 10.1083/jcb.200203091 PMID: 12235126

66. Nakasa T, Ishikawa M, Shi M, Shibuya H, Adachi N, Ochi M. Acceleration of muscle regeneration by local injection of muscle-specific miRNAs in rat skeletal muscle injury model. J Cell Mol Med. 2010; 14:2495–2505. doi: 10.1111/j.1582-4934.2009.00898.x PMID: 19754672